Metastatic CSPC: Future Directions in Care
Before closing out their discussion on novel treatment approaches to metastatic CSPC, expert panelists share hope for further evolution in care.
Optimizing Genomic Profiling in mCSPC
Expert perspectives on the utilization of genomic profiling in patients with metastatic castration-sensitive prostate cancer to impact treatment decisions.
Is There a Role for Triplet Therapy in Low-Volume mCSPC?
A brief discussion on the use of doublet versus triplet therapy in patients with low-volume metastatic prostate cancer.
Selecting Between Doublet and Triplet Therapy in mCSPC
Expert panelists consider which factors would push them toward utilizing triplet therapy in patients with metastatic castration-sensitive prostate cancer.
Case 2: Triplet Therapy in a 59-Year-Old Man With mCSPC
Centering discussion on a patient case of high-volume metastatic CSPC, expert panelists review the option of triplet therapy based on the PEACE-1 trial.
Metastatic CSPC: Educating Patients on PSA Levels
Shared insight on optimal patient monitoring strategies while administering therapy for metastatic castration-sensitive prostate cancer.
Optimizing Patient Monitoring Strategies in mCSPC
Selecting Therapy for Low-Volume mCSPC
Panelists provide comprehensive insight on treatment strategies specific to the setting of low-volume metastatic prostate cancer.
Metastatic CSPC: Rationale Behind ADT + Apalutamide Therapy
Expert oncologists review the selection of apalutamide + androgen deprivation therapy in this patient scenario of metastatic castration-sensitive prostate cancer.
Toxicities and Drug-Drug Interactions With Frontline Therapies for mCSPC
A brief discussion on the toxicities and drug-drug interactions associated with frontline therapies in metastatic CSPC and when it would be appropriate to alter treatment to mitigate toxicity.
Factors in Selecting Frontline Therapy for Patients With mCSPC
Focused discussion on drug and patient factors that aid in the selection of frontline therapy for metastatic castration-sensitive prostate cancer.
Metastatic CSPC: Is There a Continued Role for Docetaxel in the Frontline Setting?
Shared insight on the frontline use of chemotherapy options for patients with metastatic CSPC in the context of AR-targeted therapies.
Case 1: Frontline Therapy in 63-Year-Old Man With High-Volume mCSPC
After reviewing a patient scenario of metastatic castration-sensitive prostate cancer, expert panelists break down frontline treatment options in this setting.
2 Clarke Drive Cranbury, NJ 08512